Category Archives: Global News Feed

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental and epileptic encephalopathy (DEE). The EMA’s PRIME designation provides enhanced development support for priority medicines that target an unmet need and was granted based on the Part 1 data from the EMBRAVE study that showed a reduction in seizures and improvement in seizure free days, as well as preclinical data.

See more here:
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental...

LYON, France and CAMBRIDGE, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K.

See the original post here:
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease

Read more here:
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80%

Go here to see the original:
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place at the Lotte New York Palace hotel.

Continue reading here:
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

PITTSBURGH, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a human biomaterials company (“Carmell”), today announced the addition of two independent directors to their Board.

More here:
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors